Liquid Biopsy Early Cancer Detection Market - 2026-2035
Liquid Biopsy Early Cancer Detection Market reached US$ 2.48 billion in 2025 and is expected to reach US$ 7.85 billion by 2035, growing with a CAGR of 12.10% during the forecast period 2026-2035.
The Liquid Biopsy Early Cancer Detection Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Liquid Biopsy Early Cancer Detection Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
Both primary and secondary data sources have been used in the global Liquid Biopsy Early Cancer Detection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Liquid Biopsy Early Cancer Detection Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Liquid Biopsy Early Cancer Detection Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
- Multi Cancer Early Detection Tests*
- Single Cancer Early Detection Tests
- High Risk Screening Liquid Biopsy Tests
- Circulating Tumor DNA (ctDNA) *
- Cell Free DNA Methylation Biomarkers
- Cell Free RNA (cfRNA)
- Circulating Tumor Cells (CTCs)
- Exosomes and Extracellular Vesicles
- Protein Biomarkers
- Multiomics Biomarker Panels
- Others
- Blood *
- Plasma
- Serum
- Urine
- Saliva
- Others
- Next Generation Sequencing (NGS) *
- Polymerase Chain Reaction (PCR)
- Digital PCR
- Methylation Analysis
- Immunoassay Based Detection
- AI and Machine Learning Enabled Bioinformatics
- Others
- Lung Cancer *
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
- Population Screening *
- High Risk Patient Screening
- Complementary Screening with Conventional Methods
- Recurrence Risk and Residual Disease Assessment
- Hospitals *
- Discrete Manufacturing
- Process Manufacturing
- Cancer Specialty Centers
- Diagnostic Laboratories
- Academic and Research Institutes
- Preventive Healthcare Programs
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Liquid Biopsy Early Cancer Detection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Clinical shift toward methylation-led and multi-omics signal enrichment platforms
4.1.1.2. Push to detect high-mortality cancers with no routine screening pathway
4.1.1.3. Rising payer and provider interest in blood-based screening workflow efficiency
4.1.2. Restraints
4.1.2.1. Weak reimbursement case for asymptomatic broad-population testing
4.1.2.2. Physician concern over false positives and unclear diagnostic resolution pathways
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Risk-stratified screening models for aging and high-incidence populations
4.1.4.2. Preventive health bundling through executive checkups and private wellness ecosystems
4.1.5. Trends
4.1.5.1. Shift from mutation-only assays to methylation and fragmentomics-based detection
4.1.5.2. Commercial movement from single-cancer screening to multi-cancer platform positioning
4.1.6. Challenges
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors 5.3.1. Rising preference for non-invasive early cancer screening 5.3.2. Growing cancer awareness and preventive health behavior 5.3.3. Aging population increasing demand for early cancer detection
5.4. Economic Factors
5.4.1. High cost burden of late-stage cancer treatment
5.4.2. Increasing healthcare spending on early diagnosis and screening
5.4.3. Expanding private and employer-funded preventive health programs
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Multi Cancer Early Detection Tests*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Single Cancer Early Detection Tests
6.4. High Risk Screening Liquid Biopsy Tests
7. BY BIOMARKER TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
7.1.2. Market Attractiveness Index, By Biomarker Type
7.2. Circulating Tumor DNA (ctDNA) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cell Free DNA Methylation Biomarkers
7.4. Cell Free RNA (cfRNA)
7.5. Circulating Tumor Cells (CTCs)
7.6. Exosomes and Extracellular Vesicles
7.7. Protein Biomarkers
7.8. Multiomics Biomarker Panels
7.9. Others
8. BY SAMPLE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
8.1.2. Market Attractiveness Index, By Sample Type
8.2. Blood *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Serum
8.5. Urine
8.6. Saliva
8.7. Others
9. BY TECHNOLOGY
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. Next Generation Sequencing (NGS) *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Polymerase Chain Reaction (PCR)
9.4. Digital PCR
9.5. Methylation Analysis
9.6. Immunoassay Based Detection
9.7. AI and Machine Learning Enabled Bioinformatics
9.8. Others
10. BY CANCER TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.1.2. Market Attractiveness Index, By Cancer Type
10.2. Lung Cancer *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Colorectal Cancer
10.4. Breast Cancer
10.5. Prostate Cancer
10.6. Liver Cancer
10.7. Pancreatic Cancer
10.8. Ovarian Cancer
10.9. Others
11. BY APPLICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Population Screening *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2.3. High Risk Patient Screening
11.2.4. Complementary Screening with Conventional Methods
11.2.5. Recurrence Risk and Residual Disease Assessment
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Discrete Manufacturing
12.2.4. Process Manufacturing
12.3. Cancer Specialty Centers
12.4. Diagnostic Laboratories
12.5. Academic and Research Institutes
12.6. Preventive Healthcare Programs
12.7. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
14.1. U.S.
14.1.1. Canada
14.1.1.1. Mexico
14.2. Europe
14.2.1. Germany
14.2.1.1. UK
14.2.1.2. France
14.2.1.3. Russia
14.2.1.4. Spain
14.2.1.5. Italy
14.2.1.6. Poland
14.2.1.7. Rest of Europe
14.3. Latin America
14.3.1. Brazil
14.3.1.1. Argentina
14.3.1.2. Rest of Latin America
14.4. Asia-Pacific
14.4.1. China
14.4.1.1. India
14.4.1.2. Japan
14.4.1.3. Australia
14.4.1.4. South Korea
14.4.1.5. Indonesia
14.4.1.6. Malaysia
14.4.1.7. Rest of Asia-Pacific
14.5. Middle East and Africa
14.5.1. UAE
14.5.1.1. Saudi Arabia
14.5.1.2. South Africa
14.5.1.3. Israel
14.5.1.4. Turkiye
14.5.1.5. Rest of Middle East and Africa
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis - Global
15.3. Market Share Analysis - North America
15.4. Market Share Analysis - Europe
15.5. Market Share Analysis - Asia-Pacific
15.6. Mergers and Acquisitions Analysis
15.7. Partner Identification Analysis
15.8. Investment & Funding Landscape
15.9. Strategic Alliances & Innovation Pipeline
16. COMPANY PROFILES
16.1. GRAIL*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Revenue Analysis
16.1.4. Pricing Analysis
16.1.5. SWOT Analysis
16.1.6. Recent Developments
16.1.6.1. Major Deals
16.1.6.2. M&A
16.1.6.3. Collaboration
16.1.6.4. Acquisition
16.1.6.5. Joint Ventures
16.1.6.6. Innovations
16.1.7. Recent News
16.1.7.1. Events
16.1.7.2. Conferences
16.1.7.3. Symposiums
16.1.7.4. Webinars
16.2. Guardant Health
16.3. Exact Sciences Corporation
16.4. Freenome Holdings, Inc.
16.5. SeekIn Inc.
16.6. Singlera Genomics Inc.
16.7. Harbinger Health
16.8. Elypta
16.9. AnchorDx
16.10. Lucence Health Inc.
16.11. Burning Rock Biotech Limited
16.12. Natera, Inc.
16.13. Oxford BioDynamics Plc
16.14. PredOmix
16.15. Genecast Group Inc.
16.16. CORE Diagnostics
16.17. DELFI Diagnostics
16.18. ClearNote Health
16.19. ANPAC Bio-Medical Science Co., Ltd.
16.20. 20/20 BioLabs, Inc. (LIST NOT EXHAUSTIVE)
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Clinical shift toward methylation-led and multi-omics signal enrichment platforms
4.1.1.2. Push to detect high-mortality cancers with no routine screening pathway
4.1.1.3. Rising payer and provider interest in blood-based screening workflow efficiency
4.1.2. Restraints
4.1.2.1. Weak reimbursement case for asymptomatic broad-population testing
4.1.2.2. Physician concern over false positives and unclear diagnostic resolution pathways
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Risk-stratified screening models for aging and high-incidence populations
4.1.4.2. Preventive health bundling through executive checkups and private wellness ecosystems
4.1.5. Trends
4.1.5.1. Shift from mutation-only assays to methylation and fragmentomics-based detection
4.1.5.2. Commercial movement from single-cancer screening to multi-cancer platform positioning
4.1.6. Challenges
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors 5.3.1. Rising preference for non-invasive early cancer screening 5.3.2. Growing cancer awareness and preventive health behavior 5.3.3. Aging population increasing demand for early cancer detection
5.4. Economic Factors
5.4.1. High cost burden of late-stage cancer treatment
5.4.2. Increasing healthcare spending on early diagnosis and screening
5.4.3. Expanding private and employer-funded preventive health programs
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Multi Cancer Early Detection Tests*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Single Cancer Early Detection Tests
6.4. High Risk Screening Liquid Biopsy Tests
7. BY BIOMARKER TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
7.1.2. Market Attractiveness Index, By Biomarker Type
7.2. Circulating Tumor DNA (ctDNA) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cell Free DNA Methylation Biomarkers
7.4. Cell Free RNA (cfRNA)
7.5. Circulating Tumor Cells (CTCs)
7.6. Exosomes and Extracellular Vesicles
7.7. Protein Biomarkers
7.8. Multiomics Biomarker Panels
7.9. Others
8. BY SAMPLE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
8.1.2. Market Attractiveness Index, By Sample Type
8.2. Blood *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Serum
8.5. Urine
8.6. Saliva
8.7. Others
9. BY TECHNOLOGY
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. Next Generation Sequencing (NGS) *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Polymerase Chain Reaction (PCR)
9.4. Digital PCR
9.5. Methylation Analysis
9.6. Immunoassay Based Detection
9.7. AI and Machine Learning Enabled Bioinformatics
9.8. Others
10. BY CANCER TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.1.2. Market Attractiveness Index, By Cancer Type
10.2. Lung Cancer *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Colorectal Cancer
10.4. Breast Cancer
10.5. Prostate Cancer
10.6. Liver Cancer
10.7. Pancreatic Cancer
10.8. Ovarian Cancer
10.9. Others
11. BY APPLICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Population Screening *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2.3. High Risk Patient Screening
11.2.4. Complementary Screening with Conventional Methods
11.2.5. Recurrence Risk and Residual Disease Assessment
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Discrete Manufacturing
12.2.4. Process Manufacturing
12.3. Cancer Specialty Centers
12.4. Diagnostic Laboratories
12.5. Academic and Research Institutes
12.6. Preventive Healthcare Programs
12.7. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
14.1. U.S.
14.1.1. Canada
14.1.1.1. Mexico
14.2. Europe
14.2.1. Germany
14.2.1.1. UK
14.2.1.2. France
14.2.1.3. Russia
14.2.1.4. Spain
14.2.1.5. Italy
14.2.1.6. Poland
14.2.1.7. Rest of Europe
14.3. Latin America
14.3.1. Brazil
14.3.1.1. Argentina
14.3.1.2. Rest of Latin America
14.4. Asia-Pacific
14.4.1. China
14.4.1.1. India
14.4.1.2. Japan
14.4.1.3. Australia
14.4.1.4. South Korea
14.4.1.5. Indonesia
14.4.1.6. Malaysia
14.4.1.7. Rest of Asia-Pacific
14.5. Middle East and Africa
14.5.1. UAE
14.5.1.1. Saudi Arabia
14.5.1.2. South Africa
14.5.1.3. Israel
14.5.1.4. Turkiye
14.5.1.5. Rest of Middle East and Africa
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis - Global
15.3. Market Share Analysis - North America
15.4. Market Share Analysis - Europe
15.5. Market Share Analysis - Asia-Pacific
15.6. Mergers and Acquisitions Analysis
15.7. Partner Identification Analysis
15.8. Investment & Funding Landscape
15.9. Strategic Alliances & Innovation Pipeline
16. COMPANY PROFILES
16.1. GRAIL*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Revenue Analysis
16.1.4. Pricing Analysis
16.1.5. SWOT Analysis
16.1.6. Recent Developments
16.1.6.1. Major Deals
16.1.6.2. M&A
16.1.6.3. Collaboration
16.1.6.4. Acquisition
16.1.6.5. Joint Ventures
16.1.6.6. Innovations
16.1.7. Recent News
16.1.7.1. Events
16.1.7.2. Conferences
16.1.7.3. Symposiums
16.1.7.4. Webinars
16.2. Guardant Health
16.3. Exact Sciences Corporation
16.4. Freenome Holdings, Inc.
16.5. SeekIn Inc.
16.6. Singlera Genomics Inc.
16.7. Harbinger Health
16.8. Elypta
16.9. AnchorDx
16.10. Lucence Health Inc.
16.11. Burning Rock Biotech Limited
16.12. Natera, Inc.
16.13. Oxford BioDynamics Plc
16.14. PredOmix
16.15. Genecast Group Inc.
16.16. CORE Diagnostics
16.17. DELFI Diagnostics
16.18. ClearNote Health
16.19. ANPAC Bio-Medical Science Co., Ltd.
16.20. 20/20 BioLabs, Inc. (LIST NOT EXHAUSTIVE)
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
